Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

US phase II trial starts for MRA contrast agent:

This article was originally published in Clinica

Executive Summary

Advanced Magnetics has begun a phase II clinical trial in the US to test its investigational contrast agent in MR angiography (MRA). The agent, currently known as Code 7228 is a coated iron oxide product. The Cambridge, Massachusetts-based company says that preliminary results concerning the agent's safety profile and blood pool persistence - two critical elements in evaluating cardiovascular imaging agents - suggest that the product shows promise for use in cardiovascular imaging applications such as MRA.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT069749

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel